HOME Research Insight bioMérieux (France) and Becton, Dickinson and Company (US) are the Key Players in the Antimicrobial Susceptibility Testing Market



bioMérieux (France) and Becton, Dickinson and Company (US) are the Key Players in the Antimicrobial Susceptibility Testing Market


The global antimicrobial susceptibility testing market is expected to grow at a CAGR of 5.1% between 2017 and 2022. Factors such as rising prevelance of infectious diseases, emergence of multidrug-resistance are driving the growth of the antimicrobial susceptibility testing market. Furthermore, technological advancements in rapid antimicrobial susceptibility testing methods and increased funding, research grants and public-private investmants are further increasing the demand for antimicrobial susceptibility testing products, thereby driving the growth of the market.

Analysis of the market developments between 2014 and 2017 revealed that several growth strategies such as product launches, enhancements, strategic acquisitions, agreements, collaborations, and expansions were adopted by the market players to strengthen their product portfolios and maintain a competitive position in the antimicrobial susceptibility testing market. Among these business strategies, product launches and enhancements, and agreements were the most widely adopted growth strategies by the players in the antimicrobial susceptibility testing market.

bioMérieux (France) held the leading position in the global antimicrobial susceptibility testing market in 2016. The company offers a comprehensive range of solutions for microbial identification and susceptibility testing. bioMérieux has a broad and balanced geographic footprint, through its strong distribution network of 42 subsidiaries and about 20 R&D centers, which maximizes marketing opportunities for its products. The company is focused on high investment in R&D which is leading to the launch of new and technologically improved products. For instance, in December 2016, the company introduced the ETEST Ceftolazone/Tazobactam strip having MIC reading scale in μg/mL, to check susceptibility of microorganisms to Ceftolozane and Tazobactam antibiotic agents.

Becton, Dickinson and Company (US) held the second position in the antimicrobial susceptibility testing market in 2016. The company operates through two business segments, namely, BD Medical (Medication and Procedural Solutions, Medication Management Solutions, Diabetes Care, Pharmaceutical Systems, and Respiratory Solutions) and BD Life Sciences (Diagnostic Systems, Biosciences, and Preanalytical Systems). The company is focused on innovations and improving the quality of its products with increased investment in its R&D department, The R&D expenditure of the company increased from 6.1% in 2015 to 6.6% in 2016. The company adopts growth strategies such as product launches to strengthen its existing businesses and secure its leading position in the antimicrobial susceptibility testing market. For instance, in October 2016, the company launched the updated Phoenix M50 ID/AST system.

Related Reports:

Antimicrobial Susceptibility Testing Market by Product (Automated System, Disks, MIC Strips, Media), Method (Dilution, Diffusion), Type (Antibacterial, Antifungal), Application (Clinical, Drug Discovery), End User (Labs, Hospitals) - Global Forecast to 2022

Contact:
Mr. Rohan
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 
sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports